These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 23342320)

  • 21. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.
    Nowak-Göttl U; Dietrich K; Schaffranek D; Eldin NS; Yasui Y; Geisen C; Mitchell LG
    Blood; 2010 Dec; 116(26):6101-5. PubMed ID: 20833980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol.
    Ufer M
    Clin Pharmacokinet; 2005; 44(12):1227-46. PubMed ID: 16372822
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of CYP2C9 and VKORC1 genotypes on the risk of hemorrhagic complications in warfarin-treated patients: a systematic review and meta-analysis.
    Yang J; Chen Y; Li X; Wei X; Chen X; Zhang L; Zhang Y; Xu Q; Wang H; Li Y; Lu C; Chen W; Zeng C; Yin T
    Int J Cardiol; 2013 Oct; 168(4):4234-43. PubMed ID: 23932037
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenetics of warfarin.
    Kamali F; Wynne H
    Annu Rev Med; 2010; 61():63-75. PubMed ID: 19686083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
    Yin T; Miyata T
    Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High carrier prevalence of combinatorial CYP2C9 and VKORC1 genotypes affecting warfarin dosing.
    Ruaño G; Thompson PD; Villagra D; Bower B; Kocherla M; Yazdanpanah G; Seip RL; Windemuth A; White CM; Duconge J; Holford TR; Wu AH
    Per Med; 2008 May; 5(3):225-232. PubMed ID: 29783498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype.
    Kwon MJ; On YK; Huh W; Ko JW; Kim DK; Kim JS; Lee SY
    Clin Chim Acta; 2011 Nov; 412(23-24):2343-5. PubMed ID: 21782804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Contribution of
    Khaleqsefat E; Khalaj-Kondori M; Jabarpour Bonyadi M; Soraya H; Askari B
    Iran J Pharm Res; 2020; 19(3):77-85. PubMed ID: 33680011
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic determinants of response to warfarin during initial anticoagulation.
    Schwarz UI; Ritchie MD; Bradford Y; Li C; Dudek SM; Frye-Anderson A; Kim RB; Roden DM; Stein CM
    N Engl J Med; 2008 Mar; 358(10):999-1008. PubMed ID: 18322281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The pharmacogenetics of vitamin K antagonists: still a matter for discussion].
    Moreau C; Siguret V; Loriot MA
    Rev Med Interne; 2010 May; 31(5):361-8. PubMed ID: 20362363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
    Takeuchi F; McGinnis R; Bourgeois S; Barnes C; Eriksson N; Soranzo N; Whittaker P; Ranganath V; Kumanduri V; McLaren W; Holm L; Lindh J; Rane A; Wadelius M; Deloukas P
    PLoS Genet; 2009 Mar; 5(3):e1000433. PubMed ID: 19300499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.
    Molden E; Okkenhaug C; Ekker Solberg E
    Eur J Clin Pharmacol; 2010 May; 66(5):525-30. PubMed ID: 20354686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
    Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
    J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
    Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
    Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.
    Johnson JA; Gong L; Whirl-Carrillo M; Gage BF; Scott SA; Stein CM; Anderson JL; Kimmel SE; Lee MT; Pirmohamed M; Wadelius M; Klein TE; Altman RB;
    Clin Pharmacol Ther; 2011 Oct; 90(4):625-9. PubMed ID: 21900891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.